Sangamo Therapeutics Inc. has reported its financial results for the first quarter ending March 31, 2025. The company posted revenues of $6.4 million, a significant increase from $0.5 million in the same period of 2024. This increase was largely attributed to $5.0 million in revenue from a collaboration agreement with Pfizer and an additional $1.0 million from a license agreement with Sigma-Aldrich Corporation. The consolidated net loss for the quarter was $30.6 million, compared to a net loss of $49.1 million in the same quarter of the previous year. This reflects a reduction in losses, although the company continues to operate at a net loss. In terms of business updates, Sangamo Therapeutics announced a capsid license agreement with Eli Lilly and Company to deliver genomic medicines for central nervous system $(CNS)$ disease targets. The agreement includes an $18 million upfront license fee and the potential to earn up to $1.4 billion in additional fees and milestone payments, along with tiered royalties on potential net sales. Additionally, the company announced a $23 million underwritten registered direct offering of equity securities, which is expected to close on May 14, 2025. Sangamo also highlighted milestones achieved in the pathway to a biologics license application submission for isaralgagene civaparvovec in Fabry disease, as well as participation in the upcoming 28th American Society of Gene & Cell Therapy Annual Meeting with several abstracts accepted for presentation.